Slide 1 - Patterns of Care in Medical Oncology
Slide 2 - Chemotherapy for Metastatic Disease: Prior Adjuvant AC
Slide 3 - Chemotherapy for Metastatic Disease: Prior Adjuvant AC (continue)
Slide 4 - Chemotherapy for Metastatic Disease: Prior Adjuvant AC (continue)
Slide 5 - Chemotherapy for Metastatic Disease: Prior Adjuvant AC (continue)
Slide 6 - Chemotherapy for Metastatic Disease: No Prior Therapy
Slide 7 - Chemotherapy for Metastatic Disease: No Prior Therapy (continued)
Slide 8 - Chemotherapy for Metastatic Disease: No Prior Therapy (continued)
Slide 9 - Chemotherapy for Metastatic Disease: No Prior Therapy (continued)
Slide 10 - Chemotherapy for Metastatic Disease: No Prior Therapy (continued)
Slide 11 - Chemotherapy after Adjuvant AC-Paclitaxel:One Year Prior
Slide 12 - Chemotherapy after Adjuvant AC-Paclitaxel:One Year Prior (continued)
Slide 13 - Chemotherapy after Adjuvant AC-Paclitaxel:One Year Prior (continued)
Slide 14 - Chemotherapy after Adjuvant AC-Paclitaxel:One Year Prior (continued)
Slide 15 - Chemotherapy after Adjuvant AC-Paclitaxel: Five Years Prior
Slide 16 - Chemotherapy after Adjuvant AC-Paclitaxel:Five Years Prior (continued)
Slide 17 - Chemotherapy after Adjuvant AC-Paclitaxel:Five Years Prior (continued)
Slide 18 - Chemotherapy after Adjuvant AC-Paclitaxel:Five Years Prior (continued)
Slide 19 - Chemotherapy after Adjuvant AC-Paclitaxel:Five Years Prior (continued)
Slide 20 - Use of Taxanes after Adjuvant AC
Slide 21 - Clinical Use of Nanoparticle Paclitaxel
Slide 22 - Reasons for Not Using Nanoparticle Paclitaxel
Slide 23 - Schedule of Nanoparticle Paclitaxel
Slide 24 - Potential Advantages to Nanoparticle Paclitaxel
Slide 25 - Impressions of Nanoparticle Paclitaxel
Slide 26 - Impressions of Nanoparticle Paclitaxel (continued)
Slide 27 - Impressions of Nanoparticle Paclitaxel (continued)
Slide 28 - Impressions of Nanoparticle Paclitaxel (continued)
Slide 29 - Clinical Use of Bevacizumab
Slide 30 - Reasons for Not Using Bevacizumab
Slide 31 - Dosing, Scheduling and Duration of Bevacizumab
Slide 32 - Dosing, Scheduling and Duration of Bevacizumab (continued)
